Life Sciences / Medical Research / Digital Marketplace / Biospecimen Sourcing
Strategic Profile
With millions in revenue and repeatable transactions that generate real dollars, iSpecimen operates a steadier model than biotech companies betting everything on FDA calendars. The company is planting flags across high-value medical fields, partnering with U.S. cancer centers for precision oncology research and accessing more than 600,000 patients across multi-state partnerships for women's health samples.
Cyborg Score Rationale
The company booked $9.29 million in revenue in 2024 from actual, recurring platform use, validating the marketplace model. However, the stock trades at $0.25 with microcap volatility (down 83% YTD), and despite strong fundamentals, the market values iSpecimen at just $6.4 million because it sits at the intersection of logistics, life sciences, and digital infrastructure—a mix that Wall Street still struggles to categorize. Recent additions include a planned $200 million Solana blockchain-based corporate treasury, which adds execution risk.
Top Insights
iSpecimen's marketplace already works and scales, with validation separating it from microcap hopefuls living on PowerPoint slides.
The company demonstrated operational maturity by securing supply for human metapneumovirus early in 2025, positioning itself to capture demand when global biospecimen needs spike.
Recent digital transformation via Salestack platform and Solana blockchain treasury strategy suggest management is pursuing modernization and blockchain integration within life sciences.
The business model is asset-light and transaction-driven, requiring no labs or pipelines, enabling high-margin unit economics.
Named Competitors
Traditional Manual Biospecimen Sourcing — Legacy manual procurement processes
Academic and Hospital Biobanks — Sample repositories with limited online access
Recent Developments
(December 2025) $1.75 million private placement completed; Preferred stock offering expected to close December 31, 2025
(August 2025) Strategic $200M Solana blockchain-based corporate treasury announced with BlockArrow and WestPark Capital partnerships
(January 2025) Secured suppliers for human metapneumovirus samples ahead of research demand wave
(2024) Full-year revenue of $9.29 million; 76% YoY growth in Q2 2024
Open the full interactive iSpecimen Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.